Technical Analysis for HTBX - Heat Biologics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
2.17 | 2.84% | 0.06 |
HTBX closed up 2.84 percent on Friday, August 7, 2020, on 33 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Historical HTBX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | 2.84% | |
| Narrow Range Bar | Range Contraction | 2.84% | |
| NR7 | Range Contraction | 2.84% | |
| NR7-2 | Range Contraction | 2.84% | |
| Stochastic Reached Oversold | Weakness | 2.84% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company's products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; HS-410 for the bladder cancer treatment; HS-310 to treat ovarian cancer; and HS-510 for treating triple negative breast cancer. Its products also comprise HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.
Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Treatment Of Cancer Cancers Non Small Cell Lung Cancer Ovarian Cancer Vaccination Cancer Treatment HIV Vaccine Platform Technology Treatment Of Non Small Cell Lung Cancer Biotechnology Companies Bladder Cancer Cancer Vaccine Triple Negative Breast Cancer Chapel Hill Heat Biologics Neuvenge
Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Treatment Of Cancer Cancers Non Small Cell Lung Cancer Ovarian Cancer Vaccination Cancer Treatment HIV Vaccine Platform Technology Treatment Of Non Small Cell Lung Cancer Biotechnology Companies Bladder Cancer Cancer Vaccine Triple Negative Breast Cancer Chapel Hill Heat Biologics Neuvenge
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.3 |
| 52 Week Low | 0.195 |
| Average Volume | 34,091,352 |
| 200-Day Moving Average | 0.72 |
| 50-Day Moving Average | 1.40 |
| 20-Day Moving Average | 2.25 |
| 10-Day Moving Average | 2.18 |
| Average True Range | 0.36 |
| ADX | 49.23 |
| +DI | 32.26 |
| -DI | 15.01 |
| Chandelier Exit (Long, 3 ATRs ) | 3.22 |
| Chandelier Exit (Short, 3 ATRs ) | 1.95 |
| Upper Bollinger Band | 3.37 |
| Lower Bollinger Band | 1.13 |
| Percent B (%b) | 0.46 |
| BandWidth | 99.42 |
| MACD Line | 0.23 |
| MACD Signal Line | 0.31 |
| MACD Histogram | -0.0836 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.32 | ||||
| Resistance 3 (R3) | 2.31 | 2.26 | 2.30 | ||
| Resistance 2 (R2) | 2.26 | 2.22 | 2.26 | 2.29 | |
| Resistance 1 (R1) | 2.21 | 2.19 | 2.24 | 2.22 | 2.28 |
| Pivot Point | 2.16 | 2.16 | 2.17 | 2.16 | 2.16 |
| Support 1 (S1) | 2.11 | 2.12 | 2.14 | 2.12 | 2.06 |
| Support 2 (S2) | 2.06 | 2.09 | 2.06 | 2.05 | |
| Support 3 (S3) | 2.01 | 2.06 | 2.05 | ||
| Support 4 (S4) | 2.02 |
